Find Funding Opportunities

COVID-19 Funding Notices | Approved Initiative Concepts | Research Opportunity Announcements

All NINDS-related funding opportunity announcements (FOAs), request for applications (RFAs), program announcements (PAs), and other NIH Guide announcements are listed.Search the Closed Announcements tab to find expired opportunities. Search the Notices tab to find all Notices.

Learn more about award types and program directors and managers.

NINDS has a number of open positions for researchers and clinicians to contribute to exciting neuroscience programs - APPLY NOW!

Expiration Date: Friday, March 24, 2023FOA Number: RFA-NS-23-012Release Date: Monday, January 9, 2023Announcement Type: RFA
The National Institute of Neurological Disorders and Stroke (NINDS) and the Office of the Director, National Institutes of Health (OD), intend to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications for the conduct of scientific research utilizing data from expanded access (EA) to investigational drugs or biological products. These applications will target intermediate size populations of patients living with amyotrophic lateral sclerosis (ALS) who are not otherwise eligible for clinical trials for the diagnosis, mitigation, treatment, or cure of ALS ("intermediate EA protocol for ALS"). Providing the investigational drug or biological product under an intermediate EA protocol for ALS must not interfere with the initiation, conduct, or completion of clinical investigations that could support marketing approval, or otherwise compromise the potential development of medical products for the diagnosis, mitigation, treatment, or cure of ALS. Eligible applicants are clinical trial sites that participate in a phase 3 clinical trial supported by a United States (U.S.) small business concern (as defined in section 3(a) of the Small Business Act (15 U.S. C. 623(a)) that is also the U.S. Food and Drug Administration (FDA) designated sponsor of a drug or biological product for ALS that is the subject of an Investigational New Drug Application (IND). This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The FOA is expected to be published in May 2022 with an expected application due date in June 2022. This FOA will utilize the U01 activity code.
Expiration Date: Saturday, March 18, 2023FOA Number: RFA-NS-23-002Release Date: Friday, January 6, 2023Announcement Type: RFA
The purpose of this Alzheimers Disease-Related Dementia (ADRD) initiative is to promote the development and distribution of innovative technologies, methods, protocols, and biomedical materials that enhance combined human neuropathology and neuroimaging research with data aimed at understanding the underlying pathophysiology of in vivo imaging results typically associated with vascular contributions to cognitive impairment and dementia (VCID) in TBI-related dementia and other ADRD diagnoses. Resources developed under this FOA must follow open data sharing practices and are intended to expand the broader research communitys capacity to perform research aimed at neuropathologically-informed understanding of the vascular pathophysiology of clinically-relevant, in vivo neuroimaging findings.
Expiration Date: Thursday, March 2, 2023FOA Number: NOT-OD-23-044Release Date: Thursday, January 5, 2023Announcement Type: Notice of Special Interest
The goal of this Notice of Special Interest (NOSI) is to strengthen NIH-funded biomedical data repositories to better enable data discoverability, interoperability, and reuse by aligning with the FAIR and TRUST principles and using metrics to measure their effectiveness. This NOSI provides an opportunity for existing repositories to increase FAIR-ness and TRUST-worthiness to improve their usage, utility, and impact throughout the data resource lifecycle.
Expiration Date: Thursday, March 2, 2023FOA Number: RFA-PM-23-002Release Date: Friday, December 23, 2022Announcement Type: RFA
The All of Us Research Program (All of Us) within the Office of the Director (OD) encourages investigators to apply for grant applications that will advance research in high-priority mission areas of the Institutes, Centers, and Offices (ICOs) through two companion FOAs (1) one to use standard methods and approaches to analyze currently available data within the All of Us Research Programs Researcher Workbench and (2) one to develop new methods, models, and tools and use them to analyze data in the Researcher Workbench. The new tools will be made broadly available to the scientific community. This FOA uses the R03 grant mechanism to support data analysis using standard methods, while the companion FOA (link) uses the R21 mechanism for new tool development and application.
Expiration Date: Thursday, March 2, 2023FOA Number: RFA-PM-23-001Release Date: Friday, December 23, 2022Announcement Type: RFA
The All of Us Research Program (All of Us) within the Office of the Director (OD) encourages investigators to apply for grant applications that will advance research in high-priority mission areas of the Institutes, Centers, and Offices (ICOs) through two companion FOAs (1) one to use standard methods and approaches to analyze currently available data within the All of Us Research Programs Researcher Workbench and (2) one to develop new methods, models, and tools and use them to analyze data in the Researcher Workbench. The new tools will be made broadly available to the scientific community. This FOA uses the R21 grant mechanism for new tool development and application, while the companion FOA (link) uses the R03 grant mechanism to support data analysis using standard methods.
Expiration Date: Wednesday, March 1, 2023FOA Number: RFA-NS-23-009Release Date: Thursday, December 15, 2022Announcement Type: RFA
The purpose of this funding opportunity announcement (FOA) is to invite applications to participate as the National Coordinating (NCC) Center for the NIH Stroke Trials Network.Established by NINDS in 2013, the goal of the NIH StrokeNet is to harness the leadership and experience of the stroke research field to maximize efficiencies for developing, promoting and conducting high-quality, multi-site clinical trials focused on promising interventions for stroke prevention, treatment, and recovery with the objective of having a balanced portfolio between all three approaches. Multi-site exploratory and confirmatory Phase 3 clinical trials as well as biomarker-validation studies that are immediately preparatory to trials and ancillary studies designed to add scientific aims to active studies will be coordinated through a National Coordinating (NCC) and National Data Management Centers (NDMC) and multiple regional coordinating stroke centers (RCC's) with strong collaborative relationships between vascular neurology, emergency medicine, interventional neuroradiology, neurosurgery, neurointensive care, neuroimaging, stroke rehabilitation, and pediatric neurology. The network will provide a robust, standardized, and accessible infrastructure to provide the development and implementation of protocols in in stroke prevention, treatment, and recovery. The NCC will provide leadership and overall network coordination to harness the clinical science excellence and specialized expertise in stroke management at the RCC's to facilitate the recruitment of stroke patients in multiple ongoing stroke trials and studies. This FOA solicits applications for the National Coordinating Center for the Stroke Trials Network. Separate FOAs solicit applications for the Regional Coordinating Stroke Centers and the National Data Management Center.
Expiration Date: Wednesday, March 1, 2023FOA Number: RFA-NS-23-010Release Date: Thursday, December 15, 2022Announcement Type: RFA
The purpose of this funding opportunity announcement (FOA), issued by NINDS, is to invite currently awarded NIH StrokeNet centers and potential new stroke centers to participate as a Regional Coordinating Stroke Center (RCC) in the NIH StrokeNet clinical trials network. Established by NINDS in 2013, the goal of the NIH StrokeNet is to harness the leadership and experience of the stroke research field to maximize efficiencies for developing, promoting and conducting high-quality, multi-site clinical trials focused on promising interventions for stroke prevention, treatment, and recovery with the objective of having a balanced portfolio between all three approaches. Multi-site exploratory and confirmatory Phase 3 clinical trials as well as biomarker-validation studies that are immediately preparatory to trials and ancillary studies designed to add scientific aims to active studies will be coordinated through separate National Coordinating (NCC) and National Data Management Centers (NDMC). Funded RCC's in the network will be regional academic medical centers that include geographically or organizationally linked partners, clinical performance sites or satellite stroke centers that are committed to randomizing patients in NINDS-funded NIH StrokeNet clinical studies. RCC's will have both clinical science excellence and specialized expertise in stroke management, as well as a strong background in stroke research, and a proven ability to recruit stroke patients. Each RCC will also have strong collaborative relationships between vascular neurology, emergency medicine, interventional neuroradiology, neurosurgery, neurointensive care, neuroimaging, stroke rehabilitation, and pediatric neurology, thereby demonstating a commitment to offer all eligible patients the opportunity to participate in a trial conducted through the network. In addition, the NIH Stroke Trials Network will include an active stroke research career advancement program.
Expiration Date: Wednesday, March 1, 2023FOA Number: RFA-NS-23-008Release Date: Thursday, December 15, 2022Announcement Type: RFA
The purpose of this funding opportunity announcement (FOA) is to invite applications to participate as the National Data Management Center (NDMC) for the NIH Stroke Trials Network. Established by NINDS in 2013, the goal of the NIH StrokeNet is to harness the leadership and experience of the stroke research field to maximize efficiencies for developing, promoting and conducting high-quality, multi-site clinical trials focused on promising interventions for stroke prevention, treatment, and recovery with the objective of having a balanced portfolio between all three approaches. Multi-site exploratory and confirmatory Phase 3 clinical trials as well as biomarker-validation studies that are immediately preparatory to trials and ancillary studies designed to add scientific aims to active studies will be coordinated through a National Coordinating (NCC) and National Data Management Centers (NDMC) and multiple regional coordinating stroke centers (RCC's) with strong collaborative relationships between vascular neurology, emergency medicine, interventional neuroradiology, neurosurgery, neurointensive care, neuroimaging, stroke rehabilitation, and pediatric neurology. The network will provide a robust, standardized, and accessible infrastructure to provide the development and implementation of protocols in stroke prevention, treatment, and recovery. The NDMC will be responsible for centralizing, harmonizing and coordinating all aspects of data collection for studies conducted in the network. Projects will be developed both from investigators both within the network as well as from investigators or industry partners outside of the network; therefore the data center for the stroke network must be able to efficiently collaborate with all parties. This FOA solicits applications for the National Data Management Center for the Stroke Trials Network. Separate FOAs solicit applications for the Regional Coordinating Stroke Centers and the National Coordinating Center.
Expiration Date: Friday, March 10, 2023FOA Number: PAR-23-042Release Date: Wednesday, December 7, 2022Announcement Type: PAR
The National Institutes of Health (NIH) participating Institutes and Centers (ICs), in collaboration with the Global Alliance for Chronic Diseases (GACD), invite applications for implementation research focused on addressing risk factors for common noncommunicable diseases (NCDs) in World Bank-defined low- and middle-income countries (LMICs) and American Indian/Alaska Native (AI/AN) Tribal Nation populations in the United States. This Funding Opportunity Announcement (FOA) supports innovative approaches to identifying, understanding, developing, and implementingstrategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, tools, policies, and guidelines. In addition, studies to advance dissemination and implementation research methods and measures into application are encouraged. Specifically, this FOA invites applications that propose implementation research targeted to reducing the risks of NCDs in the context of cities in LMICs and/or among AI/AN Tribal Nation populations in cities in the United States, with the potential to equip policymakers and practitioners with evidence-based strategies for prevention and/or management of NCDs among disadvantaged populations globally. In the context of this FOA, "cities" include urban centers, informal settlements and slums, and periurban areas.
Expiration Date: Tuesday, March 7, 2023FOA Number: NOT-OD-23-018Release Date: Thursday, November 17, 2022Announcement Type: Notice of Special Interest
The NIH Office of Science Policy (OSP) within the Office of the Director (OD) announces the availability of administrative supplements to support 1) research on bioethical issues to develop or support the development of an evidence base that may inform future policy directions, and/or 2) certain efforts to develop or augment bioethics research capacity. Applicants may propose to supplement parent awards focused on bioethics or to address a component related to bioethics in a biomedical research study. Note that applications must be within the general scope of the parent award.